Prodapt Wins the Prestigious Salesforce Partner Innovation Award 2022
Prodapt, a leading global consulting, technology & managed services provider with a singular focus on the Connectedness industry, has been named a recipient of the Salesforce Partner Innovation Award in the "Communications" category. The prestigious award recognizes Prodapt’s contributions to Salesforce-driven digital transformation programs and the development of specific solution accelerators for the communications industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221122005351/en/
Prodapt is the winner of the Salesforce Partner Innovation Award 2022 in the Communications category (Graphic: Business Wire)
Each year, the Salesforce Partner Innovation Awards recognize the significant contributions Salesforce partners have made across clouds, industries, and the broader partner program – including consulting firms, digital agencies, resellers, and ISV partners. IDC, a global provider of market intelligence and advisory services for the IT, telecommunications, and consumer technology markets, facilitated and judged the nominations.
Prodapt tendered its nomination for the CRM transformation of Fiber Network Delivery to support multiple new operating models. The award affirms Prodapt’s continuous efforts in delivering value to its global clients by accelerating its transformation initiatives.
“In today’s world of fierce competition, customer volatility, and economic uncertainty, excellence in innovation has become a critical differentiator. The Partner Innovation Award in the Communications space signifies our track record in facilitating end-to-end CRM transformations that deliver business outcomes, leveraging our deep industry expertise.” – Smita Katariya | Vice President, Prodapt.
“Salesforce Partner Innovation Award winners, such as Prodapt, help customers grow faster and reach further in this new digital economy,” said Tyler Prince, Executive Vice President, Alliances & Channels at Salesforce. “Salesforce partners are integral to enabling digital transformation and driving customer success.”
For further details on Salesforce Partner Innovation Awards, visit: https://www.salesforce.com/news/stories/salesforce-2022-partner-innovation-award-winners/
Salesforce and others are among the trademarks of Salesforce.com, Inc.
About Prodapt
Prodapt is the largest and fastest-growing EXCLUSIVE player in the Connectedness space, serving global firms that ultimately seek to connect people.
Prodapt prides itself on long-tenured client relationships and has always been considered a valuable partner by clients. Prodapt serves global leaders across telecom, internet, media, and entertainment, such as Google, Facebook, Amazon, Microsoft, AT&T, Verizon, Liberty Latin America, Lumen, Adtran, Vodafone, Liberty Global, Windstream, Virgin Media, Rogers, KPN, BT, and Deutsche Telekom, among many others.
Prodapt is A Great Place to Work certified company with a workforce of over 5000 spread across 32 countries spanning the Americas, Europe, Africa, and Asia. Prodapt is part of the 120-year-old business conglomerate, The Jhaver Group, which employs over 22,000 people across 64+ locations globally.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221122005351/en/
Contact information
Manian Sivaramakrishnan
Head – Enterprise Marketing
maniannagasubra.s@prodapt.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom